The thyroid cancer diagnosis market size is estimated to be USD 2,730 million in 2022 and is expected to witness a CAGR of 7.59% during the forecast period 2023-2033. The increasing thyroid cancer incidence, a rise in the number of government programs and a boost in research funding, and growing importance of early detection and treatment are factors contributing to the market growth. However, lack of understanding of the precise causes of the disease and delayed disease diagnosis is expected to hinder the growth.

Segmentation

By Technique

Based on technique, the market is segregated into biopsy, imaging, blood tests, and others. In 2022, the imaging segment held the highest market share owing to the rising funding in cancer imaging and the increasing technical progress.

By Type

On the basis of type, the market is categorized into follicular carcinoma, papillary carcinoma, and others. In 2022, the papillary carcinoma segment held the highest market share due to steadily increasing occurrence.

By End-use

Based on end-use, the market is divided into research institutes, cancer diagnostic centers, hospital laboratories, and others. In 2022, the hospital laboratories segment held the highest market share owing to the increasing financial commitments to emerging and impoverished nations’ healthcare infrastructure, an increase in consumer awareness, and expanding number of patients receiving cancer diagnoses in hospitals.

Regional Markets

In 2022, North America region accounted for the highest revenue in the thyroid cancer diagnosis market and is expected to maintain its dominance during the forecast period. This is attributed to the existence of major industries, a rise in healthcare spending, and positive government initiatives, great commercial success of thyroid cancer diagnostics in the U.S. However, the Asia-Pacific region is predicted to grow at the fastest rate during the projection period owing to an increase in consumer understanding, improvements to the healthcare system, and rise in thyroid cancer incidence.

Competitor Insights

Some of the key players operating in the thyroid cancer diagnosis market are Toshiba Corporation (Japan), Thermo Fisher Scientific, Inc. (US), Siemens Healthcare GmbH (Germany), Koninklijke Philips N.V. (Netherlands), Illumina, Inc. (US), General Electric (US), F.Hoffmann-La Roche Ltd (Switzerland), Bio-Rad Laboratories, Inc (US), Agilent Technologies, Inc. (US), and Abbott (US).

This comprehensive research report focuses on the global and regional market size and forecasts of diverse segments including technique, type, and end-use from 2023 to 2033.

Report Scope:

Segmentation: Thyroid Cancer Diagnosis Market Report 2022 – 2033

Technique (Revenue, USD Million), 2022 – 2033

• Biopsy
• Imaging
• Blood Tests
• Others

Type (Revenue, USD Million), 2022 – 2033

• Follicular Carcinoma
• Papillary Carcinoma
• Others

End-use (Revenue, USD Million), 2022 – 2033

• Research Institutes
• Cancer Diagnostic Centers
• Hospital Laboratories
• Others

By Region (Revenue, USD Million), 2022 – 2033

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • UK
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of APAC
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of LATAM
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • Rest of MEA